Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemotherapy in Locally Advanced HNSCC
NCT06100497Phase 2Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Beijing Tongren Hospital. Started Oct 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06100497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100497.